anti inflammatory agent 1

Anti-inflammatory agent 1 is an anti-inflammatory compound.

Anti-Influenza agent 4 is a potent and selective inhibitor of influenza virus, inhibiting A/Parma and A/Roma strains with EC50s of 62 nM and 150 nM, respectively.

Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration.

Anxiolytic/nonsedative agent-1 (TCS 1205) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo.

anti-TB agent 1 is a potent and orally active anti-tuberculosis agent (MICs: < 2 nM against the Mtb strains H37Rv, rRMP and rINH).

ethyl 2-[3,5-bis(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate is a synthetic compound belonging to the curcumin family. It is involved in the regulation of immune response and inflammation through inhibition of the NF-κB signaling pathway, in the regulation of antioxidant response through activation of the Nrf2 signaling pathway, and in the regulation of cell survival and proliferation through inhibition of the Akt signaling pathway.

Anti-Inflammatory Peptide 1 Acetate (C45H82N12O14S2) possesses a potent anti-inflammatory activity in vivo and is a strong inhibitor of phospholipase A2 (PLA2), whose increased presence and activity results in inflammation and pain at certain bodily sites

Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]- is a compound used for antiviral activity determinations.

Anti-inflammatory agent 49 is a potent inhibitor of Drp1-Fis1 interaction, inhibits GTPase, and can be used in the study of diseases caused by mitochondrial dysfunction.

Anticonvulsant agent 1 is an anticonvulsant compound.

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.

Compound 13, also known as Anti-inflammatory agent 57 and classified as a pyranocoumarin, is a natural product extracted from the roots of Peucedanum praeruptorum. This compound possesses both multidrug-resistance (MDR) reversal properties and anti-inflammatory effects [1].

Compound 5b (Anti-inflammatory agent 61) is a potent anti-inflammatory agent that diminishes TNF-α expression in LPS-induced inflammation within RAW 264.7 cells and mitigates APAP-induced inflammation in HepG2 cells [1].

Anti-inflammatory agent 62 mitigates acetaminophen-induced hepatotoxicity in HepG2 cells by modulating inflammatory and oxidative stress pathways [1].

Compound 29 (Compound 7) is an anti-inflammatory agent that exhibits hepatoprotective activity [1].

Compound 43, also known as compound 3, is a 6-methoxyflavonol glycoside exhibiting anti-inflammatory activity. This agent, along with compound 44, is extractable from the aerial parts of Tetragonia tetragonoides [1].

Anti-inflammatory agent 58 exhibits IL-1β inhibition with an IC50 value of 1.08 μM and suppresses pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation [1].

Anti-inflammatory agent 65 (compound 29), a Hederagonic acid derivative, exhibits potent activity by inhibiting nitric oxide (NO) release, nuclear translocation of IRF3 and p65, and disrupting the STING/IRF3/NF-κB signaling pathway, thus attenuating the inflammatory response [1].

Anti-inflammatory agent 64 (compound 4b) exhibits antioxidant and anti-inflammatory activities, effectively inhibiting the secretion of IL-6 and TNF-α while also reducing paw edema [1] in both in vitro and in vivo studies.

Anti-inflammatory agent 60 (compound 21) inhibits nitric oxide production, presenting an IC50 of 12.95 μM, and reduces iNOS, phosphorylated p65, and β-catenin expression in a concentration-dependent manner [1].

Anti-inflammatory agent 63 exhibits potent inhibitory activity (EC50 = 5.33±0.57 μM) against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW264.7 cells [1].

Compound 28 (Compound 9) is an anti-inflammatory agent with hepatoprotective activity [1].

Anti-inflammatory agent 36 is an anti-inflammatory agent. It exhibited dose-dependent inhibition of LPS-induced release of TNF-a and IL-6 in active RAW 264.7 mouse macrophages, IC50=3.69uM and 3.68uM, respectively.

Compound 1 (Anti-inflammatory agent 44) is a 6-methoxyflavonol glycoside exhibiting anti-inflammatory properties, and it can be extracted from the aerial parts of Tetragonia tetragonoides [1].

Compound 5 (Anti-inflammatory agent 30) exhibits anti-inflammatory properties and demonstrates hepatoprotective activity [1].

Anti-inflammatory agent 58 is characterized by its ability to inhibit IL-1β with an IC50 value of 2.28 μM. Furthermore, it reduces pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation [1].

Compound 133, also known as Anti-osteoporosis agent-7, is a potential anti-osteoporosis agent that exhibits significant inhibition of osteoclast formation.

Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR. ROS-generating agent 1 reduces intracellular TrxR protein levels and promotes ROs-dependent apoptosis and ferroptosis in NCI-H460 cells.

Compound 3, a molluscicidal agent, is a saponin extractable from S. vesicaria [1].

Insecticidal agent 1 exhibits greater insecticidal potency than both obacunone and toosendanin.

Compound 6k, also known as Anti-hepatic fibrosis agent 2, is an orally active inhibitor of the COL1A1 enzyme and exerts anti-fibrogenic effects by targeting the Ewing sarcoma breakpoint region 1 (EWSR1)[1].

Anti-Influenza agent 5 (Compound IIB-2), a chalcone-like derivative, serves as an influenza nuclear export inhibitor. It effectively inhibits oseltamivir-resistant strains and hinders viral proliferation by obstructing the export of influenza virus nucleoprotein [1].

Anti-inflammatory agent 35 is a potent anti-inflammatory agent.

Antimalarial agent 1 is an effective antimalarial agent.

Compound 11, labeled as a weak Hepatoprotective agent-1, is a naturally occurring substance extracted from the fruits of Arctium lappa L. It demonstrates modest hepatoprotective effects when applied at a concentration of 10 μM [1].

Therapeutic Agent-1, a heteroaryl compound, serves as an enzyme replacement therapy to enhance glucocerebrosidase activity in the treatment of Gaucher disease [1].

Herbicidal agent 1 ((S)-6q) exhibits superior activity compared to its racemic form [1].

Anti-inflammatory agent 5 effectively inhibits nitric oxide (NO) production in lipopolysaccharide-induced BV-2 microglial cells.

Anti-inflammatory agent 51 is an amide/sulfonamide derivative with anti-inflammatory and potentially anti-tumor activity and inhibition of NF-κB activation, which can be used to study acute lung injury and ulcerative colitis.

Anti-MI/R injury agent 1 (compound 18), derived from Panaxatriol, represents an orally administered, potent agent against myocardial ischemia/reperfusion (MI/R) injury. It improves cell viability in cardiomyocytes subjected to oxygen-glucose deprivation and reperfusion (OGD/R)-induced injury. Furthermore, this compound significantly reduces myocardial infarction size, diminishes levels of circulating cardiac troponin I (cTnI), and mitigates cardiac tissue damage in rat models [1].

Anti-osteoporosis agent-2 (Compound 10) serves as an inhibitor of osteoclast differentiation induced by RANKL [1].

Anti-inflammatory agent 42 has anti-inflammatory activity and inhibits the expression of TNF-α and IL-6 in LPS-stimulated macrophages.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Anti-inflammatory agent 52 (compound 7c) is an orally active, selective COX-2 inhibitor with demonstrated anti-HT29 metastatic activity, causing periodic arrest in the S phase and G2/M phase. This agent exhibits moderate anti-inflammatory efficacy alongside a notable safety profile. Additionally, it possesses the uncommon capability of inhibiting tumor development in a mouse model, indicative of anti-cancer properties [1].

Compound 2v (Anti-inflammatory agent 45) demonstrates anticancer properties with direct inhibitory impacts on the proliferation of various blood malignancies, such as leukemia, lymphoma, and myeloma cell lines. It induces apoptosis and suppresses nitric oxide production in HL60 leukemia cells (IC50 = 14.7 μM) [1].

Anti-inflammatory agent 8 (compound 13) designated as an anti-inflammatory agent 8, displays enhanced activity on the COX-2 enzyme compared to COX-1, with an IC50 value of 0.09 nM. Furthermore, anti-inflammatory agent 8 exhibits oral bioavailability [1].

Anti-inflammatory agent 22 (compound 14a) is a potent orally active compound with anti-inflammatory properties. It effectively inhibits the production of TNF-α induced by LPS, exhibiting an IC50 value of 14.6 μM. Additionally, Anti-inflammatory agent 22 has demonstrated its ability to prevent adipogenesis and effectively suppress limb lymphedema volume in mice. This compound holds promise for the treatment of inflammation-related conditions, particularly lymphedematous tissue disorders [1].

Anti-inflammatory agent 56 (Compound 9), a selective COX-2 inhibitor with an IC50 of 0.54 μM, exhibits anti-oxidant and anti-inflammatory properties by inhibiting oxidative stress-induced cell death and neuroinflammation through the suppression of Keap1, COX-2, and iNOS. It also demonstrates low acute toxicity in mice with an LD50 of 1000 mg/kg [1].

Anti-inflammatory agent 38 (compound 23d) is a potent Nrf2/HO-1 pathway inhibitor, with an IC 50 value of 0.38 μM for NO . Nrf2/HO-1-IN-1 can significantly reduce the level of ROS in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory [1] .

Anti-inflammatory agent 48 functions by inhibiting the NF-κB signaling pathway and activating HO-1 expression, characterizing its role as an anti-inflammatory agent [1].